Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mismatch Repair01:20

Mismatch Repair

4.8K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
4.8K
Abnormal Proliferation02:23

Abnormal Proliferation

4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circulating tumor DNA-guided response evaluation in patients with previously treated gastroesophageal adenocarcinoma.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·2026
Same author

Neoadjuvant Single-Cycle Pembrolizumab for Stage I-III MMR-Deficient Colon Cancer: The RESET-C Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial.

Nature medicine·2026
Same author

Presurgery Physical Performance and AI-Driven Mortality Risk Prediction in Colorectal Cancer Surgery: An Observational Study.

Anesthesia and analgesia·2026
Same author

Mortality Predictions Including Pre-Admission Functional Status in ICU Patients With Delirium-A Substudy of the AID-ICU Trial.

Acta anaesthesiologica Scandinavica·2026
Same author

First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancers.

Journal for immunotherapy of cancer·2026

Related Experiment Video

Updated: Jun 2, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

210

Association Between Deficient MSH2/MSH6 Versus MLH1/PMS2 Status and Survival Rates in Localized Colorectal Cancer: A

Tobias Freyberg Justesen1, Adile Orhan1, Andreas Weinberger Rosen1

  • 1Department of Surgery, Center for Surgical Science, Zealand University Hospital, Køge, Denmark.

Annals of Surgery
|January 14, 2025
PubMed
Summary
This summary is machine-generated.

Loss of MSH2/MSH6 expression in colorectal cancer patients is linked to better overall survival compared to MLH1/PMS2 loss. This finding suggests tailored follow-up strategies for these specific patient groups.

Keywords:
colorectal cancerdeficient mismatch repair systemlocalized cancer

More Related Videos

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
28:15

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

12.3K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.4K

Related Experiment Videos

Last Updated: Jun 2, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

210
Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
28:15

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

12.3K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.4K

Area of Science:

  • Oncology
  • Gastroenterology
  • Molecular Biology

Background:

  • Mismatch repair (MMR) protein expression influences colorectal cancer (CRC) risk.
  • Prognostic differences based on specific MMR protein loss (MSH2/MSH6 vs. MLH1/PMS2) in CRC remain unclear.

Purpose of the Study:

  • To investigate the association between distinct MMR protein expression patterns (loss of MSH2/MSH6 vs. MLH1/PMS2) and survival outcomes in localized colorectal cancer.
  • To determine if specific MMR deficiencies impact overall survival (OS) and disease-free survival (DFS) in surgically treated CRC patients.

Main Methods:

  • Retrospective analysis of a Danish cohort (2009-2020) of surgically treated localized colorectal cancer patients.
  • Exclusion of patients with proficient MMR, metastatic disease, emergency surgery, or neoadjuvant therapy.
  • Propensity score matching (1:1 ratio) to compare outcomes between patients with MSH2/MSH6 loss and MLH1/PMS2 loss.

Main Results:

  • A cohort of 3,625 patients with deficient MMR localized CRC was initially identified; 556 were matched for comparison.
  • Loss of MSH2/MSH6 expression was significantly associated with improved overall survival (HR 0.60; 95% CI, 0.37-0.94).
  • No significant association was found between MSH2/MSH6 loss and disease-free survival (HR 0.84; 95% CI, 0.54-1.30).

Conclusions:

  • Loss of MSH2/MSH6 expression in localized deficient MMR colorectal cancer patients undergoing surgery is linked to better overall survival compared to MLH1/PMS2 loss.
  • These findings support the potential for differentiated follow-up strategies based on specific MMR protein deficiency patterns in colorectal cancer.